Sickle Cell Disease and the Evidence Gap: Why Better Data Means Better Asset Value

Sickle cell disease (SCD) represents one of the clearest examples of how disease burden and evidence generation remain misaligned. In the United States, SCD affects approximately 1 in 2,070 newborns overall, but 1 in 350 non-Hispanic Black newborns, reflecting a highly concentrated disease burden. This disparity is not incidental, it is foundational to how evidence should be designed, interpreted, and applied.

Despite increasing therapeutic innovation, including gene therapies and disease-modifying treatments, the underlying evidence base often fails to capture the full patient experience. Clinical trials typically emphasize controlled endpoints, while SCD is a disease defined by variability, episodic crises, long-term complications, and fragmented care pathways. This disconnect creates a critical gap between clinical evidence and real-world outcomes, limiting the ability of stakeholders to fully assess treatment value.

The Core Challenge: Evidence Does Not Reflect Real-World Disease Burden

The challenge in SCD is not simply one of access or awareness, it is an evidence architecture problem. Many datasets fail to represent how patients experience the disease over time, particularly in underserved populations where care pathways differ significantly from controlled trial environments.

For example, SCD patients frequently navigate transitions between pediatric and adult care systems, rely on emergency services during acute pain crises, and face barriers to specialty care. These factors directly influence adherence, outcomes, and long-term disease progression, yet they are often underrepresented in traditional evidence generation models.

As a result, life sciences organizations may generate robust clinical data that lacks generalizability, creating uncertainty in regulatory, payer, and real-world decision-making contexts.

Where the Evidence Gap Exists in Sickle Cell Disease

This gap is particularly important in SCD because real-world variability defines the disease itself. Without representative datasets, organizations risk building evidence that is scientifically valid but strategically incomplete.

Key Patient-Centric Realities Often Missing From Evidence

To understand SCD as an evidence problem, it is essential to look beyond traditional endpoints and consider the lived experience of patients. Critical dimensions often underrepresented in evidence generation include:

•  Frequency and severity of vaso-occlusive pain crises

•  Emergency department utilization and hospitalization patterns

•  Long-term organ damage and comorbidities

•  Access to hematology specialists and advanced therapies

•  Transitions from pediatric to adult care systems

•  Socioeconomic and geographic barriers to consistent care

These factors are not peripheral, they are central to treatment effectiveness, adherence, and real-world outcomes and is already visible in existing research.

For example, hydroxyurea, a standard-of-care therapy shown in randomized clinical trials to reduce vaso-occlusive crises and mortality, remains significantly underutilized in real-world populations, particularly among adults. Studies report utilization rates as low as 22–48% among eligible patients.

Even when prescribed, adherence remains inconsistent. Real-world studies confirm that medication adherence is often suboptimal, driven by access barriers, patient perceptions, and care fragmentation.

This gap has measurable consequences. Claims-based analyses show that adherence to hydroxyurea is associated with:

•  Fewer vaso-occlusive crises

•  Reduced hospitalizations

•  Lower emergency department utilization

•  Decreased healthcare costs

At the same time, emerging gene therapy trials demonstrate strong short-term efficacy but are conducted in highly controlled populations, limiting generalizability to broader patient groups.

Why This Is an Asset Strategy Problem, Not Just a Health Equity Issue

The implications of these evidence gaps extend beyond public health, they directly impact asset value. As highlighted in the Rubix LS equity evidence asset value white paper, evidence strategy is increasingly inseparable from asset strategy, influencing regulatory confidence, payer decisions, and market adoption.

In SCD, incomplete or non-representative evidence can lead to:

•  Reduced confidence in real-world effectiveness

•  Challenges in demonstrating long-term value to payers

•  Slower uptake in the populations most affected

•  Gaps in post-market performance data

Conversely, equity evidence, evidence generated in populations with disproportionate burden, can strengthen asset differentiation and decision confidence across the lifecycle.

From Evidence Generation to Outcomes Architecture

Addressing these challenges requires a shift from isolated data collection to integrated outcomes architecture. This approach connects disease burden, evidence gaps, study design, and decision-making into a cohesive framework.

In SCD, this means designing studies that capture both acute and longitudinal outcomes, incorporate community-based care settings, and reflect the full complexity of patient pathways. It also means building datasets that are robust enough to support AI-driven insights without reinforcing existing blind spots, ensuring that innovation is guided by evidence that truly reflects the populations most affected. 48% of life sciences executives cite AI as a major strategic influence, and 78% expect it to drive significant efficiency gains, yet only 9% report meaningful returns from scaled AI.

The Strategic Shift: From Enrollment to Representation

The industry has made progress in increasing diversity in clinical trials, but SCD highlights a deeper requirement. Representation is not just about who is enrolled, it is about whether the evidence reflects the realities of the population most affected by the disease. This includes real-world care environments, access constraints, adherence patterns, and long-term outcomes in real-world settings.

Without this level of representation, even well-designed trials may fail to answer the questions that matter most to regulators, payers, and clinicians.

Rubix LS Perspective: Turning Evidence Into Asset Value

Sickle cell disease demonstrates that equity evidence is not a parallel initiative, it is a core component of asset strategy. By generating representative, disease-specific evidence, life sciences organizations can better understand patient populations, reduce uncertainty, and make more confident decisions across the asset lifecycle.

Rubix LS approaches this challenge as a Health Outcomes Architect, integrating clinical, real-world, and patient-centered evidence to close critical gaps in underserved populations. The goal is not simply to improve data quality, but to build decision-grade evidence that reflects real-world disease burden and drives measurable value.

In SCD and across other high-burden diseases, the opportunity is clear: better evidence leads to better decisions, stronger assets, and more equitable outcomes.

If you’re working on SCD therapies, trials, or real-world evidence strategies, the key question is not whether evidence exists, it’s whether it’s decision-ready. Talk to our team about building equity evidence into your asset strategy. Rubix LS partners with life sciences organizations to design and execute disease-specific evidence strategies that strengthen decision-making, improve representativeness, and enhance asset value.